Recent Updates
Recently added Catalysts
IDYA

IDEAYA Announces Dose Expansion in Phase 1 2 Study of Darovasertib and Crizotinib Combination based on Early Clinical Efficacy in First Combination Cohort

Monday, May 10, 2021 1 min read
Key Takeaway: IDEAYA Announces Dose Expansion in Phase 1 2 Study of Darovasertib and Crizotinib Combination based on Early Clinical Efficacy in First Combination Cohort

Full Press Release Details

IDEAYA Announces Dose Expansion in Phase 1 2 Study of Darovasertib and Crizotinib Combination based on Early Clinical Efficacy in First Combination Cohort.
Tags: IDYA Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: May 10, 2021